Is ERAS Worth Buying in 2026?

Erasca, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-07

Here’s whether Erasca, Inc. Common Stock (ERAS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: trading above the 200-day MA (long-term uptrend intact); RSI 63 — healthy momentum range; strong 1-year return of +662.4%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.40% over 10 days); 3-month momentum negative (-24.1%); declining volume on rally — weak conviction (0.76x 30d avg). Currently 50.7% off its 52-week high. Score: +0/7.

Ready to act on this? 📈 Trade on Webull

ERAS is holding above its long-term 200-day MA ($8.00) but has slipped below the 50-day MA ($14.24), pointing to short-term weakness in an otherwise intact trend. An RSI of 62.6 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +662.4% compares to +24.4% for SPY (beat the market by 638.0%). The current 50.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $76,242 today
vs. S&P 500 (SPY) — same period beat market by 638.0%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($8.00)
Above 50-day MA ($14.24)
RSI(14) neutral zone (30–70) — currently 62.6
Positive return (+662.4%)
!Within 10% of period high (−50.7%)
Period Range $11.97
$1.21 $24.28
RSI (14) 62.6
0 · OversoldOverbought · 100

Key Metrics

Price$11.97
Period Return+662.4%
Period High$24.28
Period Low$1.21
Drawdown−50.7%
MA-50$14.24
MA-200$8.00
RSI (14)62.6
Avg Volume (30d)7.8M
vs. SPYbeat by 638.0%
Return Rank#26 of 1245

Trade ERAS

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers